GAITHERSBURG, MARYLAND – Early research in older adults found an experimental vaccine prevented nearly two-thirds of serious cases of a common, seasonal respiratory virus that annually kills thousands of vulnerable people — babies and senior citizens.
If further testing by vaccine developer Novavax Inc. goes well, in a few years the biotech company’s genetically engineered shot could become the first vaccine approved against respiratory syncytial virus, or RSV.
That would be a breakthrough, as drugmakers have unsuccessfully tried to create a vaccine against RSV for the last half-century. Novavax, based in Gaithersburg, Maryland, says it’s figured out how to make the immune system detect and block the tough-to-spot virus — by synthetically building one of its proteins.
There’s no treatment for RSV other than supplemental oxygen and other intensive medical care.